Biogen has decided to close down its digital ... the company and its interactions with health systems, with three locations in Boston, Zurich, and Paris employing around 150 team members.

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other oversold large cap stocks. The Fed recently reduced the funds rate by 50 basis points ...

Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:BIIB), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis ...